There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...

Scripps' Sigma factor Academic and industry researchers eager to use new tool compounds typically must reproduce synthetic schemes published in academic journals or wait months for reagent makers to list new compounds in their catalogs....

The partners formed the ROMANE consortium, which will receive €8.6 million ($11.3 million) from the Strategic Industrial Innovation (ISI) program of Bpifrance (formerly OSEO), the French innovation funding agency, to develop AB Science's masitinib to...

BioAlliance announced that it is leading the newly formed Nano Innovation for Cancer (NICE) five-member consortium, which received about €9 million ($11.7 million) in funding through the Strategic Industrial Innovation (ISI) program of bpifrance (formerly...

Theravectys S.A. , Paris, France Business: Infectious Date completed: 5/29/13 Type: Venture financing Raised: €1.2 million ($1.6 million) Investor: OSEO Note: Theravectys received the interest-free loan under OSEO's Development of Innovation assistance program. WIR Staff Infectious...

Diagnostics company Theradiag will receive €1.2 million ($1.6 million) from OSEO, the French innovation funding agency, to develop four test kits under the CaReNA project. In 2011, the companies and institution formed the CaReNA project...

The IMODI project has an expected budget of €41 million ($53.3 million), including €27.6 million ($35.9 million) in private investment. The pharmas include Sanofi, Servier, Ipsen, Pierre Fabre, Transgene and the Biofortis subsidiary of Merieux...

OSEO, the French innovation funding agency, awarded EUR 13.4 million ($17.4 million) to a public-private partnership aiming to build a national network to develop predictive experimental cancer models. Oncodesign S.A. (Dijon, France) will lead the...

R&D services company Provence launched Screening 1000, a $1.7 million research program to discover and develop an "ultra-pure molecule for the healthcare market." France's OSEO agency and Provence Technologies are co-funding the two-year project equally....

DBV announced it will use its Viaskin technology to develop Viaskin HDM to treat house dust mite allergy in children. The program will be conducted under ImmunAVia, a joint project with diagnostic company Genclis and...